Immune reconstitution hepatitis in HIV and hepatitis B coinfection, despite lamivudine therapy as part of HAART.
Hepatitis B virus (HBV) and human immunodeficiency virus (HIV) coinfection occurs commonly. The introduction of antiretroviral therapy can result in immune reconstitution hepatitis. We describe 2 coinfected patients who developed clinical flares of HBV disease, despite the inclusion of lamivudine, a drug with anti-HBV activity, in their HAART regimens. Potential strategies to manage individuals with HBV/HIV coinfection are discussed.
Drake
Anne
A
The Alfred Hospital, Melbourne, Australia. DRAKEA@svhm.org.au
Mijch
Anne
A
Sasadeusz
Joe
J
D000328:Adult; D019380:Anti-HIV Agents / Q000494:pharmacology* / Q000627:therapeutic use; D023241:Antiretroviral Therapy, Highly Active; D018791:CD4 Lymphocyte Count; D005260:Female; D015658:HIV Infections / Q000150:complications / Q000188:drug therapy / Q000276:immunology*; D006509:Hepatitis B / Q000150:complications / Q000188:drug therapy / Q000276:immunology*; D006515:Hepatitis B virus / Q000276:immunology*; D006801:Humans; D007109:Immunity / Q000187:drug effects*; D019259:Lamivudine / Q000494:pharmacology* / Q000627:therapeutic use; D008875:Middle Aged
D019380:Anti-HIV Agents; D019259:Lamivudine